Generic prices hold steady, widening distance from branded Rx

Frederick, James
September 2005
Drug Store News;9/26/2005, Vol. 27 Issue 12, p56
Trade Publication
Reports that generic drug prices in the U.S. held steady in the first quarter of 2005. Widening of the price gap between branded and generic pharmaceuticals; Impact of generic drugs on the Medicare Part D drug benefit program; Observation that price increases in branded drugs continued to exceed the rate to inflation.


Related Articles

  • Generic Rx Has Majority of Market, IMS Study Shows. Toth, Wendy // SN: Supermarket News;3/17/2008, Vol. 56 Issue 11, p25 

    The article focuses on a study which found that generic prescriptions account for a large part of the pharmaceutical market in the U.S. According to the study, 65 percent of all U.S. prescriptions dispensed are filled with generics. It also noted that as a number of big-name drugs are set to...

  • Trimming Those Healthcare Bills. Gearon, Christopher J.; Landau, Meryl Davids // U.S. News Digital Weekly;12/9/2011, Vol. 3 Issue 49, p22 

    This article discusses the issue of saving on medical expenses, relative to the entry of generic alternatives, particularly on the expensive drugs market of which patents have expired. It mentions that the expiration of patents of brand-name drugs starting 2012 up to 2015, will see the filling...

  • GP prescribing incentives hit by generic substitution.  // GP: General Practitioner;3/6/2009, p9 

    The article discusses the plan that allows generic name substitution by pharmacists over the prescribing incentives of the general practitioner (GP). It notes that under the plans being discussed by the pharmaceutical industry and the Department of Health (DoH), pharmacist could substitute drugs...

  • The adverse effects of brand-name drug prescribing. Flegel, Ken // CMAJ: Canadian Medical Association Journal;3/20/2012, Vol. 184 Issue 5, p616 

    The article focuses on the negative effect of prescribing brand-name drugs. It says that brand-name drug prescription is considered a bad practice for physicians due to its expensive prices and lack of other useful information. It mentions that brand-name drugs are designed to promote and sell...

  • Authorized generics gaining popularity. Johnsen, Michael // Drug Store News;9/26/2005, Vol. 27 Issue 12, p56 

    Reports that branded pharmaceutical companies in the U.S. are turning more and more to authorized generics as part of a viable drug life cycle. Percentage share of branded generics in the pharmaceutical market for the year ended in June 2005; Branded companies still battling generics...

  • Who really is profiting from the branded generics.  // Fort Worth Business Press;11/21/2003, Vol. 16 Issue 45, p36 

    Provides information on branded generic drugs. Description of branded generic; Reasons that the first generic company to enter usually captures most of the available generic profits; Benefits and setbacks of launching a branded generic to a drug company.

  • The International Pharmaceutical Market as a Source of Low-Cost Prescription Drugs for U.S. Patients. Kesselheim, Aaron S.; Choudhry, Niteesh K. // Annals of Internal Medicine;4/15/2008, Vol. 148 Issue 8, p614 

    In response to increasing prescription drug costs, more U.S. patients and policymakers are importing less-expensive pharmaceutical products from other countries. Large-scale prescription drug importation is currently illegal, but the U.S. Food and Drug Administration permits individuals to bring...

  • 'Broken' branded pipeline opens new generics pathways. Frederick, James // Drug Store News;9/26/2005, Vol. 27 Issue 12, p55 

    Reports that a slowdown in sales growth continues to plague the branded pharmaceutical industry in the United States. Claim by Doug Long, an industry expert from IMS Health; Competition from generic drugs; Need for branded companies to replace the lost products with new ones; Difficulty of...

  • Adherence sinks for Part D patients in 'doughnut hole'.  // Chain Drug Review;12/12/2011, Vol. 33 Issue 21, p60 

    The article reports on the 2011 research published by CVS Caremark Corp., Harvard University, Brigham and Women's Hospital showing that Medicare Part D beneficiaries entering the doughnut hole are twice as likely to stop their medications as they shift to more affordable generic drugs.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics